CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (NASDAQ:SURF) ("Surface"), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that both Institutional Shareholder Services ("ISS") and Glass, Lewis & Co. ("Glass Lewis") have recommended Surface stockholders vote "FOR" the adoption of Surface's merger agreement (the "merger agreement") with Coherus BioSciences, Inc. (NASDAQ:CHRS) ("Coherus"). ISS and Glass Lewis are the leading independent, third-party proxy advisors to thousands of institutional investors and pension funds. Both advisory firms believe the proposed adoption of

CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the second quarter 2023. "We are pleased with the progress we have made over the past several months which includes the advancement of the SRF388 and SRF114 clinical trials and the significant efforts we have undertaken towards completing our planned merger with Coherus BioSciences," said Rob Ross, M.D., chief executive officer of Surface. "To truly realize the potential of SRF388 and SRF114, it is essential that these mole

NEW YORK, June 24, 2023 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (NASDAQ:SURF) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of SURF to Coherus BioSciences, Inc. Under the terms of the agreement, SURF shareholders will receive Cohreus BioSciences, Inc. common stock at a price of $5.2831 per share for each share of SURF common stock owned. SURF shareholders will also receive certain CVRs as part of the agreement. If you are a SURF investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail

– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues – – Acquisition significantly advances Coherus' I-O pipeline with anti-IL-27 and anti-CCR8 clinical programs– – Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over Surface's anticipated net cash of $20 to $25 million at closing; Surface shareholders will also receive CVRs based on potential future payments for previously partnered assets and for potential ex-US licensing – – Coherus projects $48 - 53 million of net product revenue in 2Q 2023, and affir

– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues – – Acquisition significantly advances Coherus' I-O pipeline with anti-IL-27 and anti-CCR8 clinical programs–       – Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over Surface's anticipated net cash of $20 to $25 million at closing; Surface shareholders will also receive CVRs based on potential future payments for previously partnered assets and for potential ex-US licensing – – Coherus projects $48 - 53 million of net product revenue in 2Q 2023, and

Updated clinical data from Phase 2 studies evaluating SRF388 in both liver and lung cancer expected in the second quarter of 2023 Projected cash runway guidance remains unchanged with funding into the third quarter of 2024 CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the first quarter 2023, as well as anticipated near-term milestones. "We remain highly encouraged by the progress of our two clinical programs, SRF388 a potential first-in-class IL-27 i

CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the presentation of new preclinical data for SRF114, a fully human anti-CCR8 antibody, at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, Florida. The data will be presented in a poster session (abstract #5125) being held today. "We are highly encouraged by these new preclinical data which indicate that therapeutic depletion of CCR8 positive tumor infiltrating Tregs results in robust anti-tumorigenic activity in both checkpoint inhi

CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it will present a poster highlighting new preclinical data for SRF114, the company's fully human, afucosylated anti-CCR8 antibody, at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 14-19, 2023, in Orlando, Fl. Details on the poster presentation are below: Title: Depletion of CCR8+ tumor Treg cells with SRF114 or anti-CCR8 therapy promotes robust antitumor activity and reshapes the tumor microenvironment toward a more pr

SRF388 clinical program advancing well; updated clinical data expected in the first half of 2023 First patient dosed in a Phase 1/2 study evaluating SRF114, a potential best-in-class anti-CCR8 antibody, in patients with advanced solid tumors Cash runway guidance extended into the third quarter of 2024 CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the fourth quarter and full year 2022, as well as anticipated near-term corporate milestones. "Our teams have done an ou

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a Novel Immuno-Oncology (IO) panel discussion at the Cowen 43rd Annual Health Care Conference taking place at the Marriott Copley Place in Boston, MA.  The panel discussion will be held on Monday, March 6, 2023, at 9:10 a.m. ET, and a live audio webcast of the session may be accessed by visiting the Events page on the Investors & Media section of the Surface Oncology website. In addition, a replay of the

BTIG Research initiated coverage of Surface Oncology with a rating of Buy and set a new price target of $17.00

4 - Surface Oncology, Inc. (0001718108) (Issuer)

4 - Surface Oncology, Inc. (0001718108) (Issuer)

4 - Surface Oncology, Inc. (0001718108) (Issuer)

4 - Surface Oncology, Inc. (0001718108) (Issuer)

4 - Surface Oncology, Inc. (0001718108) (Issuer)

4 - Surface Oncology, Inc. (0001718108) (Issuer)

4 - Surface Oncology, Inc. (0001718108) (Issuer)

4 - Surface Oncology, Inc. (0001718108) (Issuer)

4 - Surface Oncology, Inc. (0001718108) (Issuer)

4 - Surface Oncology, Inc. (0001718108) (Issuer)

15-12G - Surface Oncology, Inc. (0001718108) (Filer)

EFFECT - Surface Oncology, Inc. (0001718108) (Filer)

EFFECT - Surface Oncology, Inc. (0001718108) (Filer)

S-8 POS - Surface Oncology, Inc. (0001718108) (Filer)

S-8 POS - Surface Oncology, Inc. (0001718108) (Filer)

S-8 POS - Surface Oncology, Inc. (0001718108) (Filer)

S-8 POS - Surface Oncology, Inc. (0001718108) (Filer)

S-8 POS - Surface Oncology, Inc. (0001718108) (Filer)

S-8 POS - Surface Oncology, Inc. (0001718108) (Filer)

POS AM - Surface Oncology, Inc. (0001718108) (Filer)

CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Carsten Brunn, Ph.D., will join the company's board of directors. Dr. Brunn brings more than 25 years of senior leadership experience spanning multiple biotech and pharmaceutical companies around the globe. "I am thrilled to welcome Carsten to the Surface Oncology board," said Rob Ross, M.D., chief executive officer at Surface. "Carsten is an accomplished biopharma executive with significant experience driving innovation and his counsel will be invaluable as we ad

CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointment of Theresa Boni, J.D., as general counsel and senior vice president, legal. Ms. Boni has more than 20 years of legal experience spanning the biopharmaceutical and medical device industries. "Teri is an impressive leader who brings deep legal and business acumen combined with a passion for improving the lives of patients, and we are delighted to welcome her to Surface," said Rob Ross, M.D., chief executive officer. "Her extensive life-science experience

Biopharma veteran Ben Hickey appointed to Board of Directors Lisa McGrath promoted to chief people officer; Shannon Devens promoted to senior vice president, development operations CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointments of Denice Torres to chair of the board of directors and Ben Hickey to board director. In conjunction with the board appointments, Jeff Goater will transition to board director. The company also announced internal promotions of key senior executives, naming Lisa McGrath chie

CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Denice Torres will join the company's board of directors. Ms. Torres has over 25 years of executive leadership experience in healthcare across the consumer, biopharmaceutical and medical device sectors. "I am thrilled to welcome Denice to the Surface board. She shares our commitment to bring transformational treatments to patients living with cancer," said Rob Ross, M.D., chief executive officer at Surface. "She is an insightful leader in biopharma, with significa

CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today the appointment of Henry Rath as chief business officer, and the promotions of Alison O'Neill, M.D. to chief medical officer and Jessica Fees to chief financial officer. Henry brings over twenty-five years of experience in the biotechnology industry, with roles spanning corporate finance, strategy, commercial planning, and business development. Prior to joining Surface, Henry worked at TScan Therapeutics, Seres Therapeutics, Amgen, Catabasis and Baxter Biopharmaceutic

CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the second quarter 2023. "We are pleased with the progress we have made over the past several months which includes the advancement of the SRF388 and SRF114 clinical trials and the significant efforts we have undertaken towards completing our planned merger with Coherus BioSciences," said Rob Ross, M.D., chief executive officer of Surface. "To truly realize the potential of SRF388 and SRF114, it is essential that these mole

– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues – – Acquisition significantly advances Coherus' I-O pipeline with anti-IL-27 and anti-CCR8 clinical programs– – Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over Surface's anticipated net cash of $20 to $25 million at closing; Surface shareholders will also receive CVRs based on potential future payments for previously partnered assets and for potential ex-US licensing – – Coherus projects $48 - 53 million of net product revenue in 2Q 2023, and affir

– Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues – – Acquisition significantly advances Coherus' I-O pipeline with anti-IL-27 and anti-CCR8 clinical programs–       – Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over Surface's anticipated net cash of $20 to $25 million at closing; Surface shareholders will also receive CVRs based on potential future payments for previously partnered assets and for potential ex-US licensing – – Coherus projects $48 - 53 million of net product revenue in 2Q 2023, and

Updated clinical data from Phase 2 studies evaluating SRF388 in both liver and lung cancer expected in the second quarter of 2023 Projected cash runway guidance remains unchanged with funding into the third quarter of 2024 CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the first quarter 2023, as well as anticipated near-term milestones. "We remain highly encouraged by the progress of our two clinical programs, SRF388 a potential first-in-class IL-27 i

SRF388 clinical program advancing well; updated clinical data expected in the first half of 2023 First patient dosed in a Phase 1/2 study evaluating SRF114, a potential best-in-class anti-CCR8 antibody, in patients with advanced solid tumors Cash runway guidance extended into the third quarter of 2024 CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the fourth quarter and full year 2022, as well as anticipated near-term corporate milestones. "Our teams have done an ou

– Two confirmed partial responses to SFR388 monotherapy treatment in squamous NSCLC; third patient with NSCLC experienced durable disease stabilization for over a year – – Company focusing resources on advancement of SRF388 and SRF114, extending cash runway into Q2 2024 – – Surface reports third quarter 2022 financial results – – Management to host conference call to discuss SRF388 data and other corporate updates today at 8:30 a.m. ET – CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today provided a corporate

– SRF388 clinical data presented at 2022 ASCO Annual Meeting demonstrated monotherapy responses in two different indications, combination activity and notable disease stabilization –   – Interim SRF617 clinical data anticipated in the fourth quarter of 2022 – – Multiple clinical readouts anticipated in 1H 2023, including initial safety and efficacy data from SRF388 open-label, lead-in to randomized Phase 2 study in first-line hepatocellular carcinoma (HCC) – – Cash sufficient to fund operations into 2024 – CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target th

– Cash runway extended into 2024 – – Strengthened financial position with achievement of $30 million milestone from GlaxoSmithKline and $21 million raised in the quarter through ATM facility –            – Expanding open label lead-in for SRF388 in first-line hepatocellular carcinoma (HCC), with initial data expected in the first half of 2023 – – New SRF388 clinical data to be presented at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting – CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, reported financial results

Continued progress advancing next-generation antibody portfolio, with ongoing clinical trials evaluating the broad potential of SRF388 and SRF617 across multiple tumor types Company continues to guide to cash runway through 2023 CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the fourth quarter and full year 2021, as well as anticipated 2022 corporate milestones. "Surface continues to make great progress advancing our portfolio of next-generation ant

CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results for the third quarter 2021, and provided a corporate update on recent highlights and anticipated near-term milestones. "Surface continues to make considerable progress across our pipeline of novel cancer immunotherapies, highlighted by the announcement of our planned randomized Phase 2 study evaluating SRF388, our potential first-in-class antibody therapy against IL-27, in combination with Roche's atezolizumab and bevacizumab," said Rob Ross, M.D., chi

SC 13G - Surface Oncology, Inc. (0001718108) (Subject)

SC 13G/A - Surface Oncology, Inc. (0001718108) (Subject)

SC 13G/A - Surface Oncology, Inc. (0001718108) (Subject)

SC 13G/A - Surface Oncology, Inc. (0001718108) (Subject)

SC 13G/A - Surface Oncology, Inc. (0001718108) (Subject)

SC 13G - Surface Oncology, Inc. (0001718108) (Subject)

SC 13G - Surface Oncology, Inc. (0001718108) (Subject)

SC 13G/A - Surface Oncology, Inc. (0001718108) (Subject)

SC 13G/A - Surface Oncology, Inc. (0001718108) (Subject)

SC 13G/A - Surface Oncology, Inc. (0001718108) (Subject)